Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million upfront ...

Big pharma's interest in using protein degradation as a therapeutic strategy continues with a wide-ranging deal between Pfizer and US biotech Triana Biomedicines that could be worth $1.5 billion or ...